Ignite Creation Date:
2025-12-24 @ 9:57 PM
Ignite Modification Date:
2026-02-24 @ 10:52 AM
Study NCT ID:
NCT03831932
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-19
First Post:
2019-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
NCI-2019-00572
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None